BARR PHARMACEUTICALS, INC.
Table of Contents



SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported) November 4, 2004

BARR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)
         
Delaware   1-9860   42-1612474
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)
     
400 Chestnut Ridge Road, Woodcliff Lake, NJ   07677
(Address of principal executive offices)   (Zip code)

(201) 930-3300

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 


TABLE OF CONTENTS

Item 12. Results of Operations and Financial Condition.
SIGNATURES
EX-99.0 NEWS RELEASE


Table of Contents

Item 12. Results of Operations and Financial Condition.

On November 4, 2004, Barr Pharmaceuticals, Inc. (the “Company”) issued a press release announcing results for the three months ended September 30, 2004. A copy of the release is attached hereto as Exhibit 99.0 and is incorporated herein by reference.

The Company will host a conference call and webcast at 8:00 a.m. Eastern time on Thursday, November 4th to discuss the results. A replay of the conference will be available from 12 Noon Eastern time on November 4th through 11:59 p.m. Eastern time on November 6th, and can be accessed by dialing (800) 475-6701 in the United States or (320) 365-3844 Internationally and using access code 751267. A replay of the webcast is available on the Company’s website at www.barrlabs.com in the Investor Relations / Calendar of Events section.

     
Exhibit Number
  Exhibit
99.0
  Barr Pharmaceuticals, Inc. November 4, 2004 earnings release.

 


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
  BARR PHARMACEUTICALS, INC.
 
 
Date: November 4, 2004  /s/ William T. McKee    
  William T. McKee   
  Vice President, Chief Financial Officer, and
Treasurer